Phase 2B/3 Double-blinded Placebo-controlled Efficacy Trial of Amphora® Gel for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection

Trial Profile

Phase 2B/3 Double-blinded Placebo-controlled Efficacy Trial of Amphora® Gel for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Citric acid/lactic acid/potassium bitartrate (Primary)
  • Indications Chlamydial infections; Gonorrhoea
  • Focus Therapeutic Use
  • Acronyms AMPREVENCE
  • Sponsors Evofem Biosciences
  • Most Recent Events

    • 23 Jan 2018 According to an Evofem Biosciences media release, the first patient has been enrolled in this trial.
    • 15 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 23 Oct 2017 Planned number of patients changed from 634 to 844.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top